Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group

BACKGROUND: Failure-free survival (FFS) and overall survival (OS) rates improved on Intergroup Rhabdomyosarcoma Study (IRS)-IV compared with IRS-III for patients with subset 2 (stage 1, group III non-orbit or stage 3, group I/II) low-risk embryonal rhabdomyosarcoma (ERMS) with the addition of cyclop...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Walterhouse, David O., Pappo, Alberto S., Meza, Jane L., Breneman, John C., Hayes-Jordan, Andrea, Parham, David M., Cripe, Timothy P., Anderson, James R., Meyer, William H., Hawkins, Douglas S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5662934/
https://ncbi.nlm.nih.gov/pubmed/28211936
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30613
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados